



Nominations for Appointment to the Grants Working Group (GWG)

NEW APPOINTMENTS

Christopher James Doig, MD, MSc, MA, FRCP
Professor, University of Calgary

Referral: Dr. Doig was recommended by Dr. Abba Creasey, CIRM's Vice President of Therapeutics Development.

Expertise Relevance to CIRM GWG: Dr. Doig's expertise in critical care and experience developing hospital infrastructure for Phase 1 gene therapy trials, coupled with his experience in grant reviews for Canada's equivalent to NIH, will be helpful in the review of Clinical stage program applications and Infrastructure awards.

Prior Service in CIRM Reviews: N/A

Bio:

Dr. Christopher "Chip" Doig is Professor in the Departments of Critical Care Medicine, Medicine and Community Health Sciences in the Cumming School of Medicine at the University of Calgary. Dr. Doig's research relates to outcomes research in critical care with a focus on severe sepsis and organ dysfunction. Recently, he has also conducted research in metabolomics and microbiome related to precision medicine in critical care. He has extensive experience in translational medicine, clinical trials, outcomes research including large cohorts and the use of complex datasets, medical ethics, and medical education. He has also developed ICU infrastructure to support first in human gene replacement studies of chronic diseases in adults.

Dr. Doig received his MD with distinction from University of Saskatchewan, and he trained in Vancouver and Calgary with specialization in Internal Medicine and Critical Care Medicine. He also received an MSc in Clinical Epidemiology from the University of Calgary, MSc with merit in Health Economics and Policy from the London School of Economics, an MA in Public Policy from the University of Chicago, and a certificate in Health Care Ethics from University of Washington School of Medicine. He is a past Department Head for Community Health Sciences, and a past head for the Department of Critical Care Medicine, Calgary Zone, Alberta Health Services (responsible for academic and clinical care in adult intensive care units across 4 hospitals and for approximately 1.6 million persons). He has held many leadership roles including President and Board member of the Alberta Medical Association (AMA), the board of the Canadian Medical Association (CMA), and STARS (Shock, Trauma and Rescue Society). He has also served as Chair and Science Officer for multiple funding panels for the Canadian Institutes of Health Research (the federal agency responsible for funding health and medical research in Canada) and served on the Board of the M.S.I. Foundation (an Alberta-based health research funding organization that fosters and supports research into any aspect of the provision of health and allied services).

Dr. Doig has been recognized with a number of local, provincial, national, and international awards. Among many, he has received the *McLeod Distinguished Achievement Award* for Faculty from the University of Calgary, *Alberta Health Services President's Excellence Award in Quality Improvement* for the provincial ICU delirium initiative which he co-lead, the *Alberta Medical Association Medal for Distinguished Service* for his contributions to developing critical care in Alberta, the Canadian Medical Association's *Dr. William Marsden Award in Medical Ethics*, the *E. Garner King Award* from the Canadian Critical Care Society, The *Royal Life Saving Society Bronze Benefactor Medal* for work with STARS and the *Global Sepsis Award* from the Global Sepsis Alliance. He has published in *Nature Medicine*, *New England Journal of Medicine*, *JAMA*, *Canadian Medical Association Journal*, *Academic Medicine* and leading critical care journals including the *American Journal of Critical Care Medicine*, *Critical Care Medicine*, *Intensive Care Medicine*, and the *Journal of Critical Care*.

Erin Dolan, PhD
Professor of Biochemistry and Molecular Biology, University of Georgia

Referral: Dr. Dolan was identified by the Review team's Senior Science Officer based on assessment of expertise through publications.

Expertise Relevance to CIRM GWG: Dr. Dolan's background in neuroscience, research on student learning, development, and success, coupled with her expertise reviewing for many grant review panels (related to science education, education partnerships, education reforms programs, course/curriculum and laboratory improvement programs) will be helpful in the review of Education program awards.

Prior Service in CIRM Reviews: N/A

Bio:

Dr. Erin Dolan is Professor of Biochemistry and Molecular Biology and the Georgia Athletic Association Professor of Innovative Science Education at University of Georgia in Athens, Georgia. She is also Adjunct faculty in Math and Science Education. Her research group is interested in how social psychological and sociocultural phenomena influence student learning, development, and success, using theory and methods from social and organizational psychology to understand the interpersonal and contextual factors that influence undergraduates' access to research, their personal and professional development through research, and how research experiences and research mentoring influence their educational and career trajectories.

Dr. Dolan received her PhD in Neuroscience from University of California, San Francisco. She has extensive experience in biology and life science education. She has previously served as Director of the BIOTECH Project at University of Arizona where she designed and facilitated middle and high school outreach programming and developed and sustained K-12-university partnership programming. She was also the founding Executive Director of the Texas Institute for Discovery Education in Science (TIDES) at University of Texas where she established the mission and vision for innovating teaching across the College of Natural Sciences and developed strategies and tactics to catalyze, support, and showcase innovative and evidence-based undergraduate education. She has also designed and led a wide range of professional development on active learning and mentoring, including intensive sessions for faculty to develop course-based undergraduate research experiences.

Among other commitments, Dr. Dolan serves as Senior Editor of *Life Sciences Education* and is Co-chair of the Education Committee for the American Society for Cell Biology. She has served as member of the National Academies of Science, Engineering, and Medicine's (NAEM) roundtable on Systemic Change in Undergraduate STEM Education, was an organizing member of NAEM's Participatory Workshop on Effective Mentoring, and was chair of the Gordon Research Conference on Undergraduate Biology Education Research. She has also served on the review panels for Howard Hughes Medical Institute, the National Institutes of Health, the National Science Foundation and U.S. Department of Agriculture. Among many honors, she has received the American Society for Cell Biology Distinguished Service Award, the American Society for Cell Biology Bruce Alberts Science Education Award and the Award for Exemplary Contributions to Education.

Helen Heslop, MD, DSc
Dan L Duncan Chair and Professor of Medicine and Pediatrics, Baylor College of Medicine

Referral: Dr. Heslop was identified by the Review team's Senior Science Officer based on assessment of expertise through publications.

Expertise Relevance to CIRM GWG: Dr. Heslop's clinical expertise as a hematologist/oncologist and overall research experience in developing and conducting transplant studies and cell and gene therapy studies will be helpful in the review of Clinical stage program awards and Infrastructure awards.

Prior Service in CIRM Reviews: N/A

Bio:

Dr. Helen Heslop is Dan L Duncan Chair, Professor of Medicine and Pediatrics, and Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital. She is also Interim Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine. Dr. Heslop is a physician scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve hemopoietic stem cell transplantation and cancer therapy. An additional focus for Dr. Heslop is reconstituting antiviral immunity post-transplant.

Dr. Heslop received her MB ChB, MD with a focus on Immunology and DSc in Cell Therapy from University of Otago, Dunedin, New Zealand. She has extensive experience in developing and conducting transplant studies and cell and gene therapy studies and currently holds over 20 INDs. Her initial studies were the first to demonstrate that antigen-specific cytotoxic T cells could eradicate an established malignancy, and her subsequent protocols extended the approach to Hodgkin lymphoma, non-Hodgkin lymphoma and nasopharyngeal cancer. She serves as Principal Investigator on several peer-reviewed research programs, including an NCI-funded SPORC in lymphoma, a Leukemia and Lymphoma Society Specialized Center of Research (SCOR) award (Immunotherapy of Lymphoma) and the Meg Vosberg Stand Up to Cancer Dream Team in T cell lymphoma. She is also the Principal Investigator on an NHLBI-funded training grant in Cell and Gene Therapy. She is the Associate Editor of the journal *Blood*, and has also served as editor for the journals *Molecular Therapy*, *Biology of Blood and Marrow Transplantation* and *Bone Marrow Transplantation*. She is a past President of the American Society for Gene and Cell Therapy (ASGCT), the American Society of Blood and Marrow Transplant (ASBMT) and the Foundation for Accreditation of Cell Therapy (FACT) and the past chair of the BMT CTN Steering Committee. She is an elected member of the American Association of Physicians and the National Academy of Medicine.

Anna O'Connell, MS

Higher Education Consultant; CIMER Master Facilitator, University of Wisconsin, Madison

Referral: Ms. O'Connell was recommended by Dr. Christine Pfund, a member of National Academies of Sciences, Engineering, and Medicine's Committee on Effective Mentoring in STEM.

Expertise Relevance to CIRM GWG: Ms. O'Connell's expertise in developing undergraduate/graduate education programs will be helpful in the review of Education program awards. Her consulting work in particular has exposed her to a wide variety of training programs across the country which will be helpful in gauging possible program success based on knowledge of the types of environments that will sustain training programs and types of methods (including conceptualization of mentorship) that create successful training programs.

Prior Service in CIRM Reviews: N/A

Bio:

Ms. Anna O'Connell is a higher education consultant who offers institutional consulting for departments, universities and other organizations as well as individual coaching for faculty and graduate students in order to improve training programs, particularly mentor-mentee relationships, lab culture, mental health, and departmental climate. She is also a Master Facilitator for the Center for Improvement of Mentored Experiences in Research (CIMER) at the University of Wisconsin, Madison where she is part of the core team that delivers mentorship training and institutional consulting on behalf of CIMER to organizations across the country to optimize research mentoring relationships and build a culture of mentorship.

Ms. O'Connell earned her MS in Biology at Stanford University. She also holds certifications through CIMER—to lead workshops on mentor training for faculty, mentee training for undergraduates and graduate students, and training for trainers so trainers can learn to facilitate the curriculum at their home institutions—and has been trained in Crucial Conversations, Conflict Resolution, Mental Health awareness, and Reflective Structured Dialogue to foster connection in polarized groups. As Program Coordinator and Teaching Fellow of the Howard Hughes Medical Institute Pre-Grad Program at Stanford's Department of Biological Sciences, she developed and taught a year-long experiential laboratory course for freshmen and sophomore students. This course led to several publications from students who continued their research projects after their time in the program ended. At that time, she also taught classes on genetics and an advanced seminar on biological sciences at Stanford as well as cell biology at University of California, Santa Cruz Silicon Valley Extension.

At University of North Carolina (UNC), Chapel Hill, she held various director level positions focusing on graduate recruiting and research training. She led the design and launch of UNC Chapel Hill's Biological & Biomedical Sciences (BBSP) umbrella admissions and first year training program for biomedical PhD students which brought 14 PhD programs situated across 5 different schools together to recruit and train PhD students. Her leadership of the BBSP program led to a more unified, healthy research training environment and raised awareness of issues such as mental health and the importance of relationships in student success. The BBSP program's broad reach across the UNC campus led to the establishment of an Office of Graduate Education (OGE) in the School of Medicine which now provides a wide range of services and programming focused on diversity, professional development, and research experiences for undergraduates and post-baccalaureate students. In addition to her leadership of the BBSP program, she led the administration of the OGE through her role as Director of Financial Affairs. Among other services, she has served on various grant advisory boards related to professional development, mental health,

mentoring, maximizing student diversity, post-baccalaureate research and education and broadening of experiences in scientific training.

Jamboor Vishwanatha, PhD
Regents Professor and Vice President, University of North Texas Health Science Center at Fort Worth

Referral: Dr. Vishwanatha was identified by the Review team’s Senior Science Officer based on assessment of expertise through publications.

Expertise Relevance to CIRM GWG: Dr. Vishwanatha’s experience in mentorship, networking and professional development of the biomedical research workforce, will be helpful in the review of Education program awards.

Prior Service in CIRM Reviews: N/A

Bio:

Dr. Jamboor Vishwanatha is Regents Professor, Vice President for Diversity and International Programs, Founding Director of the Texas Center for Health Disparities, Professor of Molecular and Medical Genetics and Director of the Institute for Cancer Research at University of North Texas (UNT) Health Science Center at Fort Worth, TX. Dr. Vishwanatha’s research is in cancer molecular biology, experimental therapeutics and nanotechnology. His laboratory is investigating genetic markers that predict development of aggressive prostate and breast cancers, and nanotechnology-based therapies for breast and prostate cancers. As the founding director of the Texas Center for Health Disparities, a Specialized Center of Excellence funded by the National Institutes of Health, he has directed health disparity research, education and community outreach programs.

Dr. Vishwanatha received his PhD in biological sciences from the University of South Carolina and he completed his postdoctoral fellowship at the Worcester Foundation for Experimental Biology. He is actively involved in mentorship and networking programs to diversify the biomedical research workforce, and has mentored numerous undergraduate and graduate students from underrepresented groups in biomedical sciences. He is a principal investigator of the National Research Mentoring Network, a NIH Common Fund initiative to provide mentorship, networking and professional development for a diversified biomedical and behavioral workforce. He is also a principal investigator of the NIH Specialized Center of Excellence in Health Disparities, Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity (AIM-AHEAD) Coordinating Center, as well as the Texas Community Engagement Alliance (CEAL) Consortium. For the past 12 years, he has organized the annual Texas Conference on Health Disparities that attract national speakers and participants.

Among many honors, Dr. Vishwanatha received the Presidential Award for Excellence in Science, Mathematics and Engineering Mentoring (PAESMEM) from US White House in October 2019, the nation’s highest honors for mentors who work with underrepresented groups to fully develop the nation’s human resources in STEM. Among many commitments, he serves on the external advisory committees for University of Puerto Rico-Cayey, PR; St. Mary’s University, San Antonio, Texas; Alabama State University, Montgomery, Alabama; Louisiana State University, Baton Rouge, and Savannah State University, Savannah, Georgia. He has been an active member of the American Association of Colleges of Osteopathic Medicine (AACOM) Diversity Council, the Association of American Medical Colleges Group on Research, Education and Training (AAMC GREAT) Group, the Society for the Advancement of Chicanos/Hispanics (SACNAS) to cultivate diversity in STEM education and fields and the Annual Biomedical Research Conference for Minority Students (ABRCMS).

REAPPOINTMENTS

CIRM is seeking the reappointment of the individuals listed in the table below. Their updated biographies follow.

Proposed Reappointments to GWG

Last	First	Term	Years	Expertise
Brundin	Patrik	3	6	Parkinson’s Disease; iPSC; Therapeutic Neural Transplantation

Damaser	Margot	3	6	Female Pelvic Floor Dysfunction; Incontinence; Pelvic Organ Prolapse; Neuromuscular/Extracellular Matrix Regeneration
Hefti	Franz	3	6	Neuroscience Drug Discovery and Development
Johnson	Jane	3	6	Developmental Neurobiology; Somatosensory Circuit Formation; Gene Expression; Transcriptional Control of Neural Development and Neuroendocrine Cancer
Palecek	Sean	3	6	Pluripotent Stem Cell Biology, Cardiovascular and Neurovascular Differentiation, Tissue Engineering
Rockhold	Frank	2	6	Biostatistics, Clinical Trials, Pharmacovigilance, Drug Development, Data Monitoring

Patrik Brundin, MD, PhD

Dr. Patrik Brundin is Therapeutic Area Leader for Movement Disorders at Roche as of 2022. Prior to this, he was at Van Andel Institute for 10 years where he had roles as Deputy Chief Scientific Officer and Director of the Parkinson’s Disease Center. His research focuses on pathogenic mechanisms of Parkinson’s and development of therapies that slow or stop disease progression or that repair damaged brain circuits.

Dr. Brundin earned his PhD in 1988 and MD in 1992, both from Lund University, Sweden, and is highly cited in neuroscience with more than 400 publications on Parkinson’s disease and related movement disorders. Among many awards and honors, he has received the Bernard Sanberg Memorial Award for outstanding contributions to the field of neural transplantation and repair and the Medal of Honour from the Swedish Parkinson’s Association. Among other commitments, he is a member of the World Parkinson Coalition Board of Directors and The Michael J. Fox Foundation for Parkinson’s Research Executive Scientific Advisory Board. He also served for over a decade as co-editor-in-chief of the *Journal of Parkinson’s Disease* and chair of the International Linked Clinical Trials scientific committee.

Dr. Brundin has served on the GWG for almost 12 years. He has reviewed for Clinical, Translational and Discovery stage program awards, as well as Research Leadership awards.

Margot S. Damaser, PhD

Dr. Margot Damaser is a Professor in the Department of Biomedical Engineering at the Cleveland Clinic Lerner College of Medicine, and Full Staff of the Biomedical Engineering Department, the Lerner Research Institute (LRI) and the Glickman Urological and Kidney Institute (GUKI) at Cleveland Clinic. She is also Deputy Director of the Advanced Platform Technology RR&D Center and Senior Research Career Scientist of the Louis Stokes Cleveland VA Medical Center, as well as adjunct faculty of the Department of Chemical & Biomedical Engineering and Department of Biological, Geological & Environmental Studies at Cleveland State University and adjunct faculty of the Integrative Biology Program at the University of Akron. She is widely regarded as an international expert on urodynamics, models for studying female pelvic floor disorders, and new technologies in female urology and pelvic floor disorders.

Dr. Damaser received a PhD in Bioengineering from the University of California at Berkeley and San Francisco. She completed her postdoctoral training at Lund University in Sweden and the Hospital of the University of Pennsylvania. Before relocating her lab to Cleveland, she directed the Urological Biomechanics Laboratory at Hines VA Hospital and the and Department of Urology at Loyola University School of Medicine. Dr. Damaser has over 180 peer-reviewed publications, book chapters, and/or review papers, and is developing several novel devices for improved diagnosis and treatment of incontinence, with 6 issued patents and 3 pending. Among many honors, she was elected to the American Institute for Medical and Biological Engineering College of Fellows, representing the top 2% of medical and biological engineers, for outstanding contributions to the engineering of innovative models and devices to diagnose, treat, and rehabilitate female pelvic floor disorders. Among many other services, she is a member of the VA Office of Research Oversight Field Advisory Committee, she is a member of the American Urological Association Office of Research Workgroup on Diversity, Equity & Inclusion, she serves on the Editorial Board of *Frontiers in Urology*, *Scientific Reports*, *AIMS Bioengineering*, and *Neurourology and Urodynamics*, serves on the Expert Advisory Board of *Nature Reviews Urology*, is a Review Editor for *Frontiers in Pharmacology* and *Frontiers in Physiology*, and serves on many NIH, VA, DOD, and private foundation study sections.

Dr. Damaser has served on the GWG for almost 8 years. She has reviewed for the Translational program awards.

Franz Hefti, PhD

Dr. Franz Hefti is Chief Executive Officer of Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. He has more than 20 years of experience in the biotech industry as executive, board member, co-founder and scientific advisor of many early-stage neurology companies. Before the acquisition of Prevail Therapeutics by Lilly, he held the position of Chief Development Officer at Prevail. Previously, he was Chief Operations Officer at Proclara Biosciences, a biotech company developing novel therapies for neurodegenerative diseases caused by protein misfolding, Chief Scientific Officer at Avid Radiopharmaceuticals, a company that developed Amyvid® for Alzheimer's disease brain imaging, Executive Vice President of Drug Development at Rinat Neuroscience (acquired by Pfizer), which was responsible for early development of tanezumab and fremanezumab (Ajovy®) for pain and migraines.

Dr. Hefti received his PhD from the University of Zurich and completed his postdoctoral research at the Massachusetts Institute of Technology. Earlier in his career, Dr. Hefti held senior management positions in neuroscience at Merck and Genentech. He also held positions in academia as a Professor at the University of Southern California and Associate Professor at the University of Miami, where he carried out discovery research on therapeutic approaches to neurodegenerative diseases. He has published more than 250 papers on topics in neuropharmacology.

Dr. Hefti has served as a GWG member for almost 12 years. He has reviewed for Clinical and Translational stage program awards, Preclinical Development awards, Disease Team Therapy and Development awards, and Strategic Partnership awards.

Jane Johnson, PhD

Dr. Jane Johnson is the Shirley and William S. McIntyre Distinguished Chair in Neuroscience and Professor in the Department of Neuroscience at the University of Texas (UT) Southwestern Medical Center. She is a member of the Peter O'Donnell Jr. Brain Institute, the Center for Regenerative Science and Medicine, and the Harold C. Simmons Comprehensive Cancer Center, Cancer and Development Scientific program. Her research interests include cancer biology (lineage heterogeneity and plasticity in neuroendocrine tumors), developmental neuroscience (neurogenesis and neuronal specification), somatosensory circuit formation (dorsal spinal cord) and transcription factor function in neural stem and progenitor cell biology. The research in her lab focuses on vertebrate nervous system development during the transition from proliferating neural stem cells to differentiating neurons and glia. This research uses mouse and cell line models, CRISPR, transcriptomics, and ChIP-seq to understand how transcription factors regulate neuronal differentiation and diversity, which has direct implications for stem cell biology and cancer.

Dr. Johnson received her B.S. in chemistry and her PhD in biochemistry from the University of Washington. She joined the faculty at the UT Southwestern Medical Center after completing her postdoctoral training at the California Institute of Technology. Dr. Johnson has more than 90 publications in peer-reviewed journals. She received a MERIT award from NICHD for her research in the transcriptional control of neuronal diversity and her service to NIH study sections. She has served on the Editorial Boards of the *International Journal of Developmental Neuroscience*, *Neural Development*, *WIREs Developmental Biology*, and *Developmental Biology*, and is an ad hoc reviewer for *Neuron*, *Development*, *Developmental Biology*, *Developmental Cell*, *Genes and Development*, *Journal of Neuroscience*, and *Nature Neuroscience*.

Dr. Johnson has served as a GWG member for almost 10 years. She has reviewed for Discovery program awards (Basic Biology).

Sean Palecek, PhD

Dr. Sean Palecek is the Milton J. and Maude Shoemaker Professor and Vilas Distinguished Achievement Professor in the Department of Chemical & Biological Engineering at the University of Wisconsin – Madison. He is the Bioengineering Thrust Leader for the UW Stem Cell and Regenerative Medicine Center, the Director for Research for the National Science Foundation Center for Cell Manufacturing Technologies (CMaT), and the Director for Research Innovation for the Forward BIO Institute. He is also a Fellow at the Allen Institute for Cell Science. Dr. Palecek's research lab studies how human pluripotent stem cells (hPSCs) sense and respond to microenvironmental cues in making fate choices, with a focus on differentiation to cardiovascular lineages. His lab has generated novel mechanistic insight and developed protocols for differentiation of hPSCs to cardiovascular and neurovascular cell types. They strive to engineer fully-defined, animal component-free differentiation platforms, compatible with biomanufacturing of cells and tissues for in vitro and in vivo diagnostic and regenerative medicine applications.

Dr. Palecek received his BS degree in chemical engineering from the University of Delaware, a M.S. degree in chemical engineering from the University of Illinois at Urbana-Champaign, and a PhD in chemical engineering from

Massachusetts Institute of Technology (MIT). He has authored over 150 peer-reviewed articles and 3 book chapters and has 17 patents. Among many awards, he has received the NSF Career Award, and the Lilly Young Faculty Award in Biosystems Engineering. Dr. Palecek serves as a peer reviewer for several journals including *Biomaterials*, *Journal of Cell Biology*, *Nature Protocols*, *PLoS Biology*, *Proceedings of the National Academy of Sciences USA*, and *Stem Cells* and has participated on review panels for the NSF, NIH, and several state agencies.

Dr. Palecek has served on the GWG for almost 12 years. He has reviewed for the Discovery stage and Translational stage program awards, Education program awards, New Faculty awards, Tools and Technology awards, and COVID-19 awards.

Frank W. Rockhold, PhD

Dr. Frank Rockhold is Professor of Biostatistics and Bioinformatics at the Duke University Medical Center, Interim Faculty Director of Biostatistics at the Duke Clinical Research Institute, and Affiliate Professor of Biostatistics at Virginia Commonwealth University. He has diverse research interests and consulting experience including trial design, data monitoring committees, benefit/risk evaluation, and pharmacovigilance and has been a leader in the scientific community in promoting data disclosure and transparency in clinical research.

Dr. Rockhold holds a BA in Statistics from University of Connecticut, an ScM in Biostatistics from Johns Hopkins University, and a PhD in Biostatistics from the Medical College of Virginia at Virginia Commonwealth University. His career includes numerous senior management positions in industry, including Chief Safety Officer and Senior Vice President for pharmacovigilance at GSK. Dr. Rockhold has served as Chairman of the board for CDISC (which develops and advances data standards to create a framework for generating accessible clinical research data), is currently Chairman of the board of the Frontier Science Research Foundation (which provides innovative data management and analysis for clinical trials in a variety of disease settings throughout the world) and an advisor to the European Medicines Agency (EMA). Dr. Rockhold has served on over 50 Independent Data Monitoring Committees (15 currently) across many therapeutic areas including vaccines, oncology, rare diseases, cardiology, endocrinology, dermatology, pulmonology, and neurology. He is an Elected Fellow of the American Statistical Association, the Society for Clinical Trials, and the Royal Statistical Society. He is an Accredited Professional Statistician, PStat®, and a Chartered Statistician, CStat.

Dr. Rockhold has served on the GWG for almost 6 years. He has reviewed for the Clinical stage program, Infrastructure program, and COVID-19 awards.